International Stem Cell Corporation (ISCO) is a clinical-stage biotech company developing stem cell-based therapies for neurological diseases, funded in part by two small commercial subsidiaries. The first, Lifeline Cell Technology (LCT), sells over 200 human cell culture products — including primary and stem cells, growth media, and reagents — to pharmaceutical, academic, and government researchers. LCT sells through a direct sales force, OEM partners, and distributors in Europe and Asia, with a single customer accounting for roughly 54% of total product sales. The second, Lifeline Skin Care (LSC), sells anti-aging skin care products under its ProPlus line, using extracts derived from ISCO's proprietary stem cells, sold direct-to-consumer via its own website, Amazon, and select online retailers. Together, these businesses generate roughly $9M in annual revenue. ISCO's core R&D program is built on proprietary human parthenogenetic stem cells (hpSCs), derived from unfertilized human eggs, which can be produced in a form that may be an immune match for many patients — potentially reducing the need for immune-suppression drugs post-transplant. The lead therapeutic candidate, ISC-hpNSC, completed a Phase 1 trial in Parkinson's disease, showing no serious adverse events and reductions in symptomatic "OFF-Time." Earlier-stage programs target stroke and traumatic brain injury. All therapeutic programs are pre-revenue and require substantial additional capital and regulatory approval before commercialization.